Sacubitril in combination with valsartan for chronic heart failure
Calderón M, Alcaraz A, Pichon-Riviere A, Augustovski F, García Martí S, Bardach A, Ciapponi A, López A, Rey-Ares L
Record ID 32016000903
Spanish
Authors' recommendations:
The evidence found regarding sacubitril in combination with valsartan for heart failure is scarce and of high quality. A single randomized clinical trial showed a benefit in reducing the number of all-cause deaths, cardiovascular deaths and hospitalizations related with heart failure compared with enalapril, in patients with stable Functional Class II-III (NYHA) heart failure and an ejection fraction below 35%, high natriuretic peptide and who adhere to the recommended standard treatment. No reports were found on long-term results or in specific subgroups (high risk, Chagas disease).
One clinical practice guideline from Canada and a health technology assessment from the United States recommend sacubitril/valsartan on conditional basis for mild to moderate heart failure. The coverage policies identified (United States) cover sacubitril/valsartan.
Its high cost may limit this treatment availability
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Humans
- Heart Failure
- Valine
- Valsartan
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.